PURPOSE: To provide an improved platform for simple, reliable, and cost-effective genotyping. BACKGROUND: Modern fertility treatments are becoming increasingly individualized in an attempt to optimise the follicular response and reproductive outcome, following controlled ovarian stimulation. As the field of pharmacogenetics evolve, genetic biomarkers such as polymorphisms of the follicle stimulating hormone receptor (FSHR) may be included as a predictive tool for individualized fertility treatment. However, the currently available genotyping methods are expensive, time-consuming or have a limited analytical sensitivity. Here, we present a novel version of "competitive amplification of differentially melting amplicons" (CADMA), providing an improved platform for simple, reliable, and cost-effective genotyping. METHODS: Two CADMA based assays were designed for the two common polymorphisms of the FSHR gene: rs6165 (c.919A > G, p. Thr307Ala, FSHR 307) and rs6166 (c.2039A > G, p. Asn680Ser, FSHR 680). To evaluate the reliability of the new CADMA-based assays, the genotyping results were compared with two conventional PCR based genotyping methods; allele-specific PCR (AS-PCR) and Sanger sequencing. RESULTS: The genotype frequencies for both polymorphisms were 35 % (TT), 42 % (CT), and 23 % (CC), respectively. A 100 % accordance was observed between the CADMA-based genotyping results and sequencing results, whereas 5 discrepancies were observed between the AS-PCR results and the CADMA-based genotyping results. Comparing the CADMA-based assays to (AS-PCR) and Sanger sequencing, the CADMA based assays showed an improved analytical sensitivity and a wider applicability. CONCLUSIONS: The new assays provide a reliable, fast and user-friendly genotyping method facilitating a wider implication in clinical practise.
PURPOSE: To provide an improved platform for simple, reliable, and cost-effective genotyping. BACKGROUND: Modern fertility treatments are becoming increasingly individualized in an attempt to optimise the follicular response and reproductive outcome, following controlled ovarian stimulation. As the field of pharmacogenetics evolve, genetic biomarkers such as polymorphisms of the follicle stimulating hormone receptor (FSHR) may be included as a predictive tool for individualized fertility treatment. However, the currently available genotyping methods are expensive, time-consuming or have a limited analytical sensitivity. Here, we present a novel version of "competitive amplification of differentially melting amplicons" (CADMA), providing an improved platform for simple, reliable, and cost-effective genotyping. METHODS: Two CADMA based assays were designed for the two common polymorphisms of the FSHR gene: rs6165 (c.919A > G, p. Thr307Ala, FSHR 307) and rs6166 (c.2039A > G, p. Asn680Ser, FSHR 680). To evaluate the reliability of the new CADMA-based assays, the genotyping results were compared with two conventional PCR based genotyping methods; allele-specific PCR (AS-PCR) and Sanger sequencing. RESULTS: The genotype frequencies for both polymorphisms were 35 % (TT), 42 % (CT), and 23 % (CC), respectively. A 100 % accordance was observed between the CADMA-based genotyping results and sequencing results, whereas 5 discrepancies were observed between the AS-PCR results and the CADMA-based genotyping results. Comparing the CADMA-based assays to (AS-PCR) and Sanger sequencing, the CADMA based assays showed an improved analytical sensitivity and a wider applicability. CONCLUSIONS: The new assays provide a reliable, fast and user-friendly genotyping method facilitating a wider implication in clinical practise.
Authors: Hermann M Behre; Robert R Greb; Andrea Mempel; Barbara Sonntag; Ludwig Kiesel; Petra Kaltwasser; Ewald Seliger; Friedrich Röpke; Jörg Gromoll; Eberhard Nieschlag; Manuela Simoni Journal: Pharmacogenet Genomics Date: 2005-07 Impact factor: 2.089
Authors: Ellen R Klinkert; Egbert R te Velde; Sjerp Weima; Peter M van Zandvoort; Rob G J M Hanssen; Philomeen R Nilsson; Frank H de Jong; Caspar W N Looman; Frank J M Broekmans Journal: Reprod Biomed Online Date: 2006-11 Impact factor: 3.828
Authors: Cameron N Gundry; Steven F Dobrowolski; Y Ranae Martin; Thomas C Robbins; Lyle M Nay; Nathan Boyd; Thomas Coyne; Mikeal D Wall; Carl T Wittwer; David H-F Teng Journal: Nucleic Acids Res Date: 2008-04-29 Impact factor: 16.971
Authors: Carlo Alviggi; Kim Pettersson; Salvatore Longobardi; Claus Yding Andersen; Alessandro Conforti; Pasquale De Rosa; Roberto Clarizia; Ida Strina; Antonio Mollo; Giuseppe De Placido; Peter Humaidan Journal: Reprod Biol Endocrinol Date: 2013-06-01 Impact factor: 5.211
Authors: Wolfgang Koechling; Daniel Plaksin; Glenn E Croston; Janni V Jeppesen; Kirsten T Macklon; Claus Yding Andersen Journal: Endocr Connect Date: 2017-04-27 Impact factor: 3.335
Authors: Tanni Borgbo; Hana Klučková; Milan Macek; Jana Chrudimska; Stine Gry Kristensen; Lise Lotte Hansen; Claus Yding Andersen Journal: Front Endocrinol (Lausanne) Date: 2017-06-02 Impact factor: 5.555